Literature DB >> 3706456

Can ophthalmologists correctly identify patients defaulting from pilocarpine therapy?

M A Kass, M Gordon, D W Meltzer.   

Abstract

We determined whether clinical measurements and assessments available to ophthalmologists could be used to identify patients who default from pilocarpine treatment. The measurements and assessments included intraocular pressure, pupillary diameter, pupillary reactivity to light, the patient's report of compliance, the physician's prediction of compliance, the patient's log of pilocarpine administration, and the weight of pilocarpine eyedrops utilized. Compliance with the pilocarpine regimen was measured with an unobtrusive eyedrop medication monitor. Intraocular pressure and pupillary diameter did not correlate with compliance to the regimen as measured by the eyedrop monitor. Pupillary reaction to light, the physician's prediction of compliance, a daily log of pilocarpine administration, the weight of pilocarpine utilized, and the patient's report of compliance correlated modestly with compliance as measured by the monitor (range of correlations, 0.19 to 0.24). However, none of these measures taken by itself or combined in any manner adequately distinguished patients with lower rates of compliance from those with higher rates of compliance. At present, the eyedrop monitor is the only reliable method for detecting patients who default from treatment.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3706456     DOI: 10.1016/0002-9394(86)90940-2

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  37 in total

1.  Patterns of Glaucoma Medication Adherence over Four Years of Follow-Up.

Authors:  Paula Anne Newman-Casey; Taylor Blachley; Paul P Lee; Michele Heisler; Karen B Farris; Joshua D Stein
Journal:  Ophthalmology       Date:  2015-08-25       Impact factor: 12.079

2.  Accuracy and performance of a commercially available Dosing Aid.

Authors:  Tara H Cronin; Malik Y Kahook; Kira L Lathrop; Robert J Noecker
Journal:  Br J Ophthalmol       Date:  2006-08-17       Impact factor: 4.638

3.  Measurement of patient compliance and the interpretation of randomized clinical trials.

Authors:  R Vander Stichele
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 4.  The electronic medication event monitor. Lessons for pharmacotherapy.

Authors:  J Urquhart
Journal:  Clin Pharmacokinet       Date:  1997-05       Impact factor: 6.447

Review 5.  [Glaucoma in the aged--barriers to understanding and compliance].

Authors:  T S Dietlein
Journal:  Ophthalmologe       Date:  2006-09       Impact factor: 1.059

Review 6.  Pharmacoeconomic consequences of variable patient compliance with prescribed drug regimens.

Authors:  J Urquhart
Journal:  Pharmacoeconomics       Date:  1999-03       Impact factor: 4.981

7.  Correlation of quality of life with clinical symptoms and signs at the time of glaucoma diagnosis.

Authors:  R P Mills
Journal:  Trans Am Ophthalmol Soc       Date:  1998

8.  Noncompliance with glaucoma medication in Korean patients: a multicenter qualitative study.

Authors:  Myoung Hee Park; Kyu-Dong Kang; Jungil Moon
Journal:  Jpn J Ophthalmol       Date:  2012-10-12       Impact factor: 2.447

9.  Risk Factors Associated with Progression to Blindness from Primary Open-Angle Glaucoma in an African-American Population.

Authors:  Alexander Pleet; Melanie Sulewski; Rebecca J Salowe; Raymond Fertig; Julia Salinas; Allison Rhodes; William Merritt Iii; Vikas Natesh; Jiayan Huang; Harini V Gudiseva; David W Collins; Venkata Ramana Murthy Chavali; Paul Tapino; Amanda Lehman; Meredith Regina-Gigiliotti; Eydie Miller-Ellis; Prithvi Sankar; Gui-Shuang Ying; Joan M O'Brien
Journal:  Ophthalmic Epidemiol       Date:  2016-06-27       Impact factor: 1.648

10.  An evaluation of how glaucoma patients use topical medications: a pilot study.

Authors:  Tony Tsai; Alan L Robin; Judson P Smith
Journal:  Trans Am Ophthalmol Soc       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.